Ilona Hartmane

Prof. Ilona Hartmane


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2024 in Plastic and Aesthetic Nursing
Verified
Journal Article
Closed access
IHIlona Hartmane
Ilona Hartmane
The purpose of this study was to identify the heterogeneity of atopic dermatitis and to identify key genetic factors. This can lead to new approaches and personalized treatment strategies. I conducted a literature review of three scientific publication platforms (i.e., PubMed, Cochrane Library, Scopus) for records published between July 2011 and July 2023 using key words related to the genetics of atopic dermatitis. The high heritability and genetic pleiotropia of atopic dermatitis emphasize the importance of its genetic predisposition and interaction with concomitant diseases. The study also shows the role of various genes associated with immunity and inflammatory reactions, as well as the high heritability of atopic dermatitis, particularly among twins. Genetic mutations, specifically polymorphisms of genes encoding immune factors and inflammatory responses, determine an individual’s predisposition to atopic dermatitis. Research findings also point to genetic aspects associated with other skin conditions such as psoriasis and vitiligo, confirming the existence of common genetic mechanisms between these diseases. Specifically, polymorphisms of the filaggrin gene have been found to be key genetic determinants of atopic dermatitis. I analyzed the genetic basis of atopic dermatitis, emphasizing the importance of genetic determinants and their interaction with the immune system and extracellular matrix. This study contributes to the understanding of the mechanisms of atopic dermatitis and opens new perspectives for individualized treatments.

1 June 2021 in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
Verified
Journal Article
Open access
PDF file
IHIlona Hartmane
Ilona Hartmane
IIIveta Ivdra
Iveta Ivdra
IMIngmārs Mikažāns
Ingmārs Mikažāns
VBVanda Bondare-Ansberga
Vanda Bondare-Ansberga
This article is aimed to provide an overview of psoriasis clinical aspects, available treatment options for moderate-to-severe psoriasis in Baltics and summarises recommendations of authors for use of different biologicals in psoriasis patients under a limited reimbursement environment.

23 October 2023 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
IHIlona Hartmane
Ilona Hartmane
IIIveta Ivdra
Iveta Ivdra
IMIngmars Mikazans
Ingmars Mikazans
APAleksejs Princevs
Aleksejs Princevs
ITIrena Teterina
Irena Teterina
LRLelde Reinberga
Lelde Reinberga
Background: There are few data on the use of ceftriaxone in pregnant women diagnosed with syphilis. The aim of this study was to investigate the safety and efficacy of ceftriaxone as an alternative treatment option for syphilis during pregnancy. Methods: A retrospective analysis of 79 pregnant women diagnosed with syphilis and treated with ceftriaxone was conducted. Results: No cases of intolerance, Jarisch-Herxheimer reactions, or allergic reactions were recorded. The average time to seronegativation for secondary syphilis with symptoms was 6.14 months ± 2.76, and for latent forms, it was 7.52 months ± 1.84. Patients received no additional treatment. No serious adverse drug reactions were reported. Conclusions: Data from our study support the use of ceftriaxone as an effective and safe alternative treatment for pregnant women diagnosed with syphilis when penicillin therapy is contraindicated or unavailable.

1 October 2021 in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
Verified
Journal Article
Open access
PDF file
IHIlona Hartmane
Ilona Hartmane
IIIveta Ivdra
Iveta Ivdra
IMIngmārs Mikažāns
Ingmārs Mikažāns
VBVanda Bondare-Ansberga
Vanda Bondare-Ansberga
Psoriasis is one of the most common autoimmune dermatoses with a chronic relapsing course. Biologic therapy should be initiated for patients with moderate to severe psoriasis when conventional systemic therapy and phototherapy are ineffective, or their use is limited due to comorbidities. In Latvia, adalimumab is the first choice of biologic drugs for treatment of psoriasis. The correlation between changes in cellular and humoral immunological parameters and clinical signs based on immunological data from psoriasis patients are evaluated in the publication.

1 February 2016 in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
Verified
Journal Article
Open access
PDF file
IHIlona Hartmane
Ilona Hartmane
IMIngmārs Mikažāns
Ingmārs Mikažāns
IIIveta Ivdra
Iveta Ivdra
ADAndra Dērveniece
Andra Dērveniece
IAInāra Ančupāne
Ināra Ančupāne
Psoriasis is a chronic relapsing skin disease presenting with erythematous and papulous lesions with infiltration and extensive desquamation on the skin surface. It is a genetically determined, multifactorial dermatosis where genetic, immune, and environmental factors play significant roles in its development. In Latvia in treatment of different forms of extensively spreading psoriasis, PUVA (psoralen and ultraviolet A light therapy), a combined method, is administered, applying long-wave UVA radiation with wavelength 320–400 nm in combination with photosensibilisator 8-metoxypsoralen and medium wave length UVB radiation narrow-band phototherapy — 311 nm using specialised TL-01 lamps. The aim of our clinical investigation was to determine the efficacy of narrow-band phototherapy (UVB 311 nm) in the complex treatment of patients with different severity of extensive psoriatic lesions treated in the Clinical Centre of Skin and Sexually Transmitted Diseases. Cases of clinical data of 260 patients with widely spread psoriasis were analysed. In the Group 1 (n = 102) receiving narrow-band UVB therapy, the mean and cumulative UVB dosage was 1.8 ± 0.6 and 21.5 ± 3.8 J/cm2, respectively, whereas in Group 2 (n = 91) it was 2.2 ± 0.1 and 27.7 ± 8.0 J/cm2. To obtain clinical recovery, 18 to 30 procedures were necessary (average 22 ± 4.1) with total irradiation dose received 110 ± 4.6 J/cm2. In 67 patients of the control group, PUVA therapy was administered, and positive therapeutic efficacy was observed in all patients. Clinical recovery was obtained in 86.2% in patients of the Group 1, in 82.4% — of Group 2, and in 80% — in 67 patients of the control group. Narrow-band (311 nm) UVB phototherapy is currently one of the leading pathogenetical methods of treatment of patients with widespread psoriasis. It has high efficacy, good tolerability, does not have severe side effects and restrictions in use, in comparison with traditional PUVA therapy.

1 April 2024 in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
Verified
Journal Article
Open access
PDF file
IHIlona Hartmane
Ilona Hartmane
IMIngmars Mikažāns
Ingmars Mikažāns
IIIveta Ivdra
Iveta Ivdra
VBVanda Bondare-Ansberga
Vanda Bondare-Ansberga
ITIrena Teterina
Irena Teterina
EBElga Bataraga
Elga Bataraga
Methotrexate (MTX) is one of the first-line systemic treatment options in patients with moderate-to-severe plaque psoriasis and can be combined with narrow band UVB phototherapy (Nb-UVB). However, such a combination is rarely used for optimal duration due to safety and efficacy concerns. The aim of this study was to assess efficacy and safety of methotrexate (MTX) combination with low doses of Nb-UVB versus MTX monotherapy in patients with moderate-to-severe plaque psoriasis in a real-world setting. Retrospective psoriasis patient medical chart review was performed for the period from 2013 till 2019. The combination therapy group (Group 1, n = 74) received MTX 10 mg s/c once a week for four to six weeks and 311 nm UVB phototherapy according to the skin type and protocol of administration — three times a week; undergoing 10–24 procedures in the treatment course. The monotherapy group (Group 2, n = 57) was treated, using MTX as monotherapy 2.5 mg two times a day orally for five days (4–6 treatment courses in total). The combination therapy group achieved decrease of mean PASI at the end of the 2nd week of treatment by 38% vs monotherapy group 21%. Combination of low dose subcutaneous MTX and Nb-UVB therapy provides better treatment outcomes and normalisation of immunochemical parameters than for MTX monotherapy. This combination also showed a favourable tolerability profile.